The study indicated a favorable risk-to-benefit ratio for pembrolizumab in this population, but the overall and progression-free survival did not reach statistical significance per the specified criteria.
← all excerpts
Hepatocellular carcinoma in patients with renal dysfunction: Pathophysiology, prognosis, and treatment challenges.
1
—
—